In this issue:
Subcutaneous vs. intravenous ravulizumab in eculizumab-experienced PNH
Cyclophosphamide with either busulfan or TBI in B-cell ALL
Deauville score + quantitative PET parameters for predicting CAR T-cell efficacy
Potentially inappropriate medications in geriatric transplant survivors
Lenalidomide and eltrombopag for low- or intermediate-risk MDS
Brentuximab + nivolumab after autologous SCT for high-risk classical Hodgkin lymphoma
Outcomes in CLL previously treated with covalent BTK and BCL2 inhibitors
Allogeneic SCT in adults with inborn errors of immunity
Belumosudil in bronchiolitis obliterans syndrome
Dasatinib + peg-interferon-α2b in chronic-phase CML
Please login below to download this issue (PDF)